86 related articles for article (PubMed ID: 1804593)
1. Immunobiology of Clostridium perfringens type A: passive protection of NMRI mice. Western blot analysis of immunoreactive polypeptides.
Traub WH; Bauer D; Wolf U
Chemotherapy; 1991; 37(5):318-26. PubMed ID: 1804593
[TBL] [Abstract][Full Text] [Related]
2. Heterologous protection against alpha toxins of Clostridium perfringens and Staphylococcus aureus induced by binding domain recombinant chimeric protein.
Uppalapati SR; Kingston JJ; Murali HS; Batra HV
Vaccine; 2014 May; 32(25):3075-81. PubMed ID: 24699467
[TBL] [Abstract][Full Text] [Related]
3. Quality assurance of C. perfringens epsilon toxoid vaccines--ELISA versus mouse neutralisation test.
Rosskopf-Streicher U; Volkers P; Noeske K; Werner E
ALTEX; 2004; 21 Suppl 3():65-9. PubMed ID: 15057410
[TBL] [Abstract][Full Text] [Related]
4. [Comparative evaluation of the methods of determining perfringens A antitoxin].
Shemanova GF; Trapezov EV; Musina EE; Vlasova EV; Panteleev EI
Biull Eksp Biol Med; 1983 Nov; 96(11):82-4. PubMed ID: 6315110
[TBL] [Abstract][Full Text] [Related]
5. Modified toxin-binding inhibition (ToBI) test for epsilon antitoxin determination in serum of immunized rabbits.
Sobrinho EM; Cangussu AS; Brandi IV; Sari RS; Almeida AC; Colen F; Quintilio W; Santos HO
Vet Immunol Immunopathol; 2010 Nov; 138(1-2):129-33. PubMed ID: 20709411
[TBL] [Abstract][Full Text] [Related]
6. Immunization with recombinant bivalent chimera r-Cpae confers protection against alpha toxin and enterotoxin of Clostridium perfringens type A in murine model.
Shreya D; Uppalapati SR; Kingston JJ; Sripathy MH; Batra HV
Mol Immunol; 2015 May; 65(1):51-7. PubMed ID: 25645504
[TBL] [Abstract][Full Text] [Related]
7. Toxin-neutralizing antibodies protect against Clostridium perfringens-induced necrosis in an intestinal loop model for bovine necrohemorrhagic enteritis.
Goossens E; Verherstraeten S; Valgaeren BR; Pardon B; Timbermont L; Schauvliege S; Rodrigo-Mocholí D; Haesebrouck F; Ducatelle R; Deprez PR; Van Immerseel F
BMC Vet Res; 2016 Jun; 12(1):101. PubMed ID: 27297520
[TBL] [Abstract][Full Text] [Related]
8. A recombinant carboxy-terminal domain of alpha-toxin protects mice against Clostridium perfringens.
Nagahama M; Oda M; Kobayashi K; Ochi S; Takagishi T; Shibutani M; Sakurai J
Microbiol Immunol; 2013 May; 57(5):340-5. PubMed ID: 23668605
[TBL] [Abstract][Full Text] [Related]
9. Control of Clostridium perfringens vaccines using an indirect competitive ELISA for the epsilon toxin component - examination of the assay by a collaborative study.
Rosskopf-Streicher U; Volkers P; Werner E
Pharmeuropa Bio; 2004 Jan; 2003(2):91-6. PubMed ID: 14960265
[TBL] [Abstract][Full Text] [Related]
10. Passive protection of NMRI mice against Serratia marcescens: comparative efficacy of commercial human IgG immunoglobulin preparations and rabbit anti-O, -H, -K, -life cell and -protease immune sera.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Jul; 254(4):480-8. PubMed ID: 6202079
[TBL] [Abstract][Full Text] [Related]
11. Production and evaluation of a monoclonal antibody to Clostridium perfringens type D epsilon toxin.
El-Enbaawy MI; Abdalla YA; Hussein AZ; Osman RM; Selim SA
Egypt J Immunol; 2003; 10(1):77-81. PubMed ID: 15719625
[TBL] [Abstract][Full Text] [Related]
12. Immunization with an alphatoxin variant 121A/91-R212H protects mice against Clostridium perfringens alphatoxin.
Schoepe H; Neubauer A; Schlapp T; Wieler LH; Baljer G
Anaerobe; 2006 Feb; 12(1):44-8. PubMed ID: 16701610
[TBL] [Abstract][Full Text] [Related]
13. [Standardization of the control technics of Clostridium perfringens vaccine. Use of a reference vaccine].
Bousicaux A
Dev Biol Stand; 1976; 32():45-61. PubMed ID: 187511
[TBL] [Abstract][Full Text] [Related]
14. Potential protective immunogenicity of recombinant Clostridium perfringens α-β2-β1 fusion toxin in mice, sows and cows.
Zeng J; Deng G; Wang J; Zhou J; Liu X; Xie Q; Wang Y
Vaccine; 2011 Jul; 29(33):5459-66. PubMed ID: 21641956
[TBL] [Abstract][Full Text] [Related]
15. Beta toxin is essential for the intestinal virulence of Clostridium perfringens type C disease isolate CN3685 in a rabbit ileal loop model.
Sayeed S; Uzal FA; Fisher DJ; Saputo J; Vidal JE; Chen Y; Gupta P; Rood JI; McClane BA
Mol Microbiol; 2008 Jan; 67(1):15-30. PubMed ID: 18078439
[TBL] [Abstract][Full Text] [Related]
16. Colostral transfer of Clostridium perfringens type C beta antitoxin in swine.
Matisheck PH; McGinley M
Am J Vet Res; 1986 May; 47(5):1132-3. PubMed ID: 2872843
[TBL] [Abstract][Full Text] [Related]
17. [Use of the reversed passive hemagglutination in detection of Clostridium botulinum type A, B, and E toxin (author's transl)].
Sonnenschein B
Zentralbl Bakteriol Orig A; 1978 Apr; 240(2):221-34. PubMed ID: 207051
[TBL] [Abstract][Full Text] [Related]
18. The effect of passive immunization on active immunity against Clostridium perfringens type D in lambs.
Odendaal MW; Visser JJ; Bergh N; Botha WJ
Onderstepoort J Vet Res; 1989 Dec; 56(4):251-5. PubMed ID: 2560536
[TBL] [Abstract][Full Text] [Related]
19. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
[TBL] [Abstract][Full Text] [Related]
20. Passive protection of NMRI mice with commercial, intravenously applicable human immunoglobulin IgG preparations against Serratia marcescens.
Traub WH
Chemotherapy; 1986; 32(6):530-6. PubMed ID: 3542407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
